A First-in-Human Phase I Trial of the Oral P-STAT3 Inhibitor WP1066 in Patients With Recurrent Malignant Glioma

Authors

John de Groot
Martina Ott
Jun Wei
Cynthia Kassab
Dexing Fang
Hinda Najem
Barbara O'Brien
Shiao-Pei Weathers
Carlos Kamiya Matsouka
Nazanin K Majd
Rebecca A Harrison
Gregory N Fuller
Jason T Huse
James P Long
Raymond Sawaya
Ganesh Rao
Tobey J MacDonald
Waldemar Priebe
Michael DeCuypere
Amy B Heimberger

Publication Date

6-1-2022

Journal

CNS Oncology

DOI

10.2217/cns-2022-0005

PMID

35575067

PMCID

PMC9134932

PubMedCentral® Posted Date

5-16-2022

PubMedCentral® Full Text Version

Post-print

Keywords

Brain Neoplasms, Disease Progression, Glioblastoma, Glioma, Humans, Pyridines, STAT3 Transcription Factor, Tyrphostins, glioblastoma, Phase I, STAT3 inhibitor, toxicity

Published Open-Access

yes

Recommended Citation

Groot, John de; Ott, Martina; Wei, Jun; et al., "A First-in-Human Phase I Trial of the Oral P-STAT3 Inhibitor WP1066 in Patients With Recurrent Malignant Glioma" (2022). Faculty, Staff and Student Publications. 3107.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/3107